Lung cancer begins when cells in a lung become abnormal and begin growing out of control. When the abnormal cancer cells grow, they can form into a tumor and even spread to other areas of the body (metastasize).
Review this section's important information about lung cancer diagnosis, staging, and treatment options, as well as lung cancer patient and survivor resources as you prepare for an appointment with your oncologist. After reviewing these sections, ask your cancer care team any additional questions that you may have about your individual situation.
If your doctor suspects you may have lung cancer, they will order tests to look for cancerous cells and make a lung cancer diagnosis. Your doctor might recommend various tests, including a chest x-ray, biopsy, sputum cytology or imaging tests to diagnose either Non-Small Cell or Small Cell Lung Cancer.
There are two types of lung cancer, Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC), named based on the type of cells found in the cancer and how the cells appear viewed under a microscope. The cancer cells of each type grow and spread differently, affecting the types of treatment used.
Your type and stage of your lung cancer, as well as various other factors, will dictate your treatment plan. The lung cancer doctors at NYOH work together with you to develop your treatment plan. Your treatment options may include surgery, chemotherapy, radiation therapy, immunotherapy, laser therapy, endoscopic stent placement, or targeted therapy.
From support groups to chemotherapy classes, hereditary risk assessment to financial support through our NYOH Community Cancer Foundation, the cancer specialists at New York Oncology Hematology are here for you every step of the way. We encourage you to learn more and take advantage of our supportive care services.
Lung cancer care is becoming increasingly personalized with tailored treatments targeting the unique cellular characteristics of tumors. To support this, NYOH is participating in the MYLUNG Study, an observational/interventional research trial to deepen our understanding of the disease and improve care for non-small lung cancer (NSCLC) patients. Participation will not impact your prescribed treatment plan.
MYLUNG brings together diverse organizations across the US Oncology network to observe up to 12,000 NSCLC patients over a five-year period. You may be eligible to take part in this study if you have been diagnosed with non-squamous, non-small cell lung cancer. If you’re interested in participating in this study, please complete our inquiry form.
New York Oncology Hematology cancer researchers, partnered with the US Oncology Network, lead the way in finding new cancer treatment options through clinical trials at all NYOH locations.
We are always looking for the latest cancer treatment options for our patients and are also involved with many other types of breakthrough lung cancer research studies. Click for a full list of our available lung cancer research studies.
Read real stories from cancer survivors, including lung cancer survivors, right in your community. Learn about their patient experience and why they trust New York Oncology Hematology with their cancer care.
NYOH Joins MYLUNG Consortium, Aiming to Advance Use of Precision Medicine for Metastatic Non-Small Cell Lung Cancer Patients
New York Oncology Hematology (NYOH) recently joined the MYLUNG consortium, a large-scale community-based research study to advance precision medicine options for non-small cell lung cancer (NSCLC) patients.
Dr. Evangelist Discusses Advances in Lung Cancer Research
Dr. Evangelist discusses the advancements in clinical research trials for lung cancer as part of a special report by the Times Union newspaper and WMHT-TV.